In vitro activity of BAY v 3522, a new oral cephalosporin.
The in vitro activity of BAY v 3522 was compared with the activities of cephalexin, cefaclor, cefuroxime, cefixime, and amoxicillin-clavulanate. MICs (in micrograms/ml) of BAY v 3522 were as follows: Staphylococcus spp. (except for oxacillin-resistant strains), 0.13 to 1; Streptococcus spp. (except for some viridans group streptococci), less than or equal to 0.015 to 0.25; Enterococcus faecalis, 2 to 8; other enterococci, 0.5 to greater than 32; beta-lactamase-negative Haemophilus influenzae and Branhamella catarrhalis, 0.13 to 1; beta-lactamase-positive H. influenzae and B. catarrhalis, 0.5 to 4; Pasteurella multocida, 0.06 to 0.25; and members of the family Enterobacteriaceae, 0.5 to greater than 32. Among the cephalosporins, BAY v 3522 was the most active against gram-positive cocci and cefixime was the most active against gram-negative bacilli; BAY v 3522 was similar in activity to amoxicillin-clavulanate against most species.
Fass
R J
RJ
Department of Internal Medicine, Ohio State University College of Medicine, Columbus 43210.
D000284:Administration, Oral; D000658:Amoxicillin / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects; D052160:Benzothiazoles; D002511:Cephalosporins / Q000008:administration & dosage / Q000494:pharmacology*; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000494:pharmacology; D004755:Enterobacteriaceae / Q000187:drug effects; D006193:Haemophilus influenzae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects; D010325:Pasteurella / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects
D052160:Benzothiazoles; D002511:Cephalosporins; D002969:Clavulanic Acids; C064738:Bay v 3522; D019818:Clavulanic Acid; D000658:Amoxicillin